REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

05/04/2018 12:10

RNS Number : 9785J
Oxford Biomedica PLC
05 April 2018
 

 
 
 
 
 
 
Director Dealings / Market Share Purchase
 
Oxford, UK - 05 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 05 April 2018 Peter Nolan, Chief Business Officer acquired ordinary shares of 1p each ("Ordinary Shares") in the Company for his wife and himself as follows:
 
 




 


 


 


 


Interest after purchase




Director / PDMR


Title


Price per share (p)


Number of Ordinary Shares acquired


Number of Ordinary Shares


% of total
issued share capital




Peter Nolan


Chief Business Officer


10.8p


371,450


2,289,771


0.07%




 
The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.                   
 
 
 
-Ends-
 




For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson,  Chief Executive Officer
Stuart Paynter, Chief Financial Officer


 
Tel: +44 (0)1865 783 000




 
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
 


 
Tel: +44 (0)20 3709 5700




 
Notes for editors
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBBGDSRGGBGIU